346 related articles for article (PubMed ID: 16117801)
1. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes.
Lang J; MacKie RM
J Invest Dermatol; 2005 Sep; 125(3):575-9. PubMed ID: 16117801
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
3. The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type.
Stadelmeyer E; Heitzer E; Resel M; Cerroni L; Wolf P; Dandachi N
J Invest Dermatol; 2014 Feb; 134(2):548-550. PubMed ID: 24026210
[No Abstract] [Full Text] [Related]
4. Relationship between DNA ploidy-related parameters and the deletions in mismatch repair genes MLH1 and MSH2 in lentigo maligna and malignant melanomas.
Korabiowska M; Viehöver M; Schlott T; Berger H; Droese M; Brinck U
Arch Dermatol Res; 2001 May; 293(5):219-25. PubMed ID: 11409565
[TBL] [Abstract][Full Text] [Related]
5. KIT and BRAF mutational status in a patient with a synchronous lentigo maligna melanoma and a gastrointestinal stromal tumor.
Matin RN; Gonzalez D; Thompson L; Lambert SR; Bakr F; Dhomen N; Marais R; McGregor JM; Szlosarek P; Cerio R; Harwood CA
Am J Clin Dermatol; 2012 Feb; 13(1):64-5. PubMed ID: 22175303
[No Abstract] [Full Text] [Related]
6. TERT gene amplification is associated with poor outcome in acral lentiginous melanoma.
Diaz A; Puig-Butillé JA; Muñoz C; Costa D; Díez A; Garcia-Herrera A; Carrera C; Badenas C; Solé F; Malvehy J; Puig S; Alos L
J Am Acad Dermatol; 2014 Oct; 71(4):839-41. PubMed ID: 25219713
[No Abstract] [Full Text] [Related]
7. Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).
Di Carlo V; Stiller CA; Eisemann N; Bordoni A; Matz M; Curado MP; Daubisse-Marliac L; Valkov M; Bulliard JL; Morrison D; Johnson C; Girardi F; Marcos-Gragera R; Šekerija M; Larønningen S; Sirri E; Coleman MP; Allemani C;
Br J Dermatol; 2022 Sep; 187(3):364-380. PubMed ID: 35347700
[TBL] [Abstract][Full Text] [Related]
8. [Dubreuilh melanoma: and epidemiologic and prognostic study].
Tournillac I; Picot MC; Dereure O; Guilhou JJ; Guillot B
Ann Dermatol Venereol; 1999 Oct; 126(10):676-80. PubMed ID: 10604003
[TBL] [Abstract][Full Text] [Related]
9. Lentigo maligna: melanoma in situ on chronically sun-damaged skin.
Reed JA; Shea CR
Arch Pathol Lab Med; 2011 Jul; 135(7):838-41. PubMed ID: 21732771
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600 mutations and pathological features in Japanese melanoma patients.
Yamazaki N; Tanaka R; Tsutsumida A; Namikawa K; Eguchi H; Omata W; Oashi K; Ogawa T; Hayashi A; Nakamura N; Tsuta K
Melanoma Res; 2015 Feb; 25(1):9-14. PubMed ID: 25051202
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
12. Unusual variants of melanoma: fact or fiction?
Sagebiel RW
Semin Oncol; 1996 Dec; 23(6):703-8. PubMed ID: 8970590
[TBL] [Abstract][Full Text] [Related]
13. Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.
Baiter M; Schuler G; Hartmann A; Schneider-Stock R; Heinzerling L
Dermatology; 2015; 231(2):127-33. PubMed ID: 26138035
[TBL] [Abstract][Full Text] [Related]
14. Extrafacial Lentigo Maligna: A Report on 14 Cases and a Review of the Literature.
Martínez-Leboráns L; Garcías-Ladaria J; Oliver-Martínez V; Alegre de Miquel V
Actas Dermosifiliogr; 2016 Oct; 107(8):e57-63. PubMed ID: 27180003
[TBL] [Abstract][Full Text] [Related]
15. Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type.
Tannous ZS; Lerner LH; Duncan LM; Mihm MC; Flotte TJ
Hum Pathol; 2000 Jun; 31(6):705-8. PubMed ID: 10872664
[TBL] [Abstract][Full Text] [Related]
16. Melanoma--clinical, dermatoscopical, and histopathological morphological characteristics.
Situm M; Buljan M; Kolić M; Vučić M
Acta Dermatovenerol Croat; 2014; 22(1):1-12. PubMed ID: 24813835
[TBL] [Abstract][Full Text] [Related]
17. BRAF point mutations in primary melanoma show different prevalences by subtype.
Sasaki Y; Niu C; Makino R; Kudo C; Sun C; Watanabe H; Matsunaga J; Takahashi K; Tagami H; Aiba S; Horii A
J Invest Dermatol; 2004 Jul; 123(1):177-83. PubMed ID: 15191558
[TBL] [Abstract][Full Text] [Related]
18. Clinical and histopathological characterization of cutaneous melanomas in the melanoblastoma-bearing Libechov minipig model.
Vincent-Naulleau S; Le Chalony C; Leplat JJ; Bouet S; Bailly C; Spatz A; Vielh P; Avril MF; Tricaud Y; Gruand J; Horak V; Frelat G; Geffrotin C
Pigment Cell Res; 2004 Feb; 17(1):24-35. PubMed ID: 14717842
[TBL] [Abstract][Full Text] [Related]
19. Comparison between lentigo maligna melanoma and other histogenetic types of malignant melanoma of the head and neck. Scottish Melanoma Group.
Cox NH; Aitchison TC; Sirel JM; MacKie RM
Br J Cancer; 1996 Apr; 73(7):940-4. PubMed ID: 8611411
[TBL] [Abstract][Full Text] [Related]
20. Management of lentigo maligna and lentigo maligna melanoma: seminars in surgical oncology.
Arlette JP; Trotter MJ; Trotter T; Temple CL
J Surg Oncol; 2004 Jul; 86(4):179-86. PubMed ID: 15221924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
